PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
The cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway detects cytosolic DNA to activate innate immune responses. Poly(ADP-ribose) polymerase inhibitors (PARPi) selectively target cancer cells with DNA repair deficiencies such as those caused by BRCA1 mutations or ERCC1 defects. Using isogenic cell lines and patient-derived samples, we showed that ERCC1-defective non-small cell lung cancer (NSCLC) cells exhibit an enhanced type I IFN transcriptomic signature and that low ERCC1 expression correlates with increased lymphocytic infiltration. We demonstrated that clinical PARPi, including olaparib and rucaparib, have cell-autonomous immunomodulatory properties in ERCC1-defective NSCLC and BRCA1-defective triple-negative breast cancer (TNBC) cells. Mechanistically, PARPi generated cytoplasmic chromatin fragments with characteristics of micronuclei; these were found to activate cGAS/STING, downstream type I IFN signaling, and CCL5 secretion. Importantly, these effects were suppressed in PARP1-null TNBC cells, suggesting that this phenotype resulted from an on-target effect of PARPi on PARP1. PARPi also potentiated IFN-γ-induced PD-L1 expression in NSCLC cell lines and in fresh patient tumor cells; this effect was enhanced in ERCC1-deficient contexts. Our data provide a preclinical rationale for using PARPi as immunomodulatory agents in appropriately molecularly selected populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“various FDA-approved and experimental PARP inhibitors have been shown to drive robust type I IFN secretion downstream of increased cytosolic availability of ssDNA or micronuclei (DNAcontaining structures generally formed by faulty mitoses) in a variety of tumors, including (but not limited to) BRCA1- and BRCA2-deficient neoplasms (Chabanon et al., 2019; Ding et al., 2018; Pantelidou et al., 2019;”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chabanon et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, the administration of PARP inhibitors has been associated with PD-L1 upregulation in various cancer cells regardless of BRCA1/2 status, presumably as a consequence of type I IFN or IFNG signaling (Chabanon et al., 2019; Jiao et al., 2017; Sen et al., 2019; Shen et al., 2019).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chabanon et al., 2019
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · cited 2×
“While various DDR defects have been shown to critically contribute to the accumulation of mutations in the tumor genome, only some of them have proven their predictive value as biomarkers of response to anti-PD-(L)1 therapy (6, 45).”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 2×
“Both ERCC1 and BRCA1 defects confer sensitivity to platinum-based therapy (26, 27) and PARP inhibitors (PARPi) (28, 29), and while PARPi have demonstrated their efficacy in advanced BRCA-deficient breast cancers (30), these”
BackgroundSelf-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 1×
“Very recent impressive results of large phase III trials in NSCLC have reported unprecedented improvements in overall survival and progression free survival when using anti-programmed death receptor 1 or -ligand 1 (anti-PD-(L)1) in first-line therapy (1, 2).”
BackgroundGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · cited 12×
“Other DNA repair defects, such as BRCA1/2 mutations have been found enriched in ICI responders (12).”
BackgroundInfluentialGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · cited 1×
“Other DNA repair defects, such as BRCA1/2 mutations have been found enriched in ICI responders (12).”
BackgroundOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294 · cited 1×
“Both ERCC1 and BRCA1 defects confer sensitivity to platinum-based therapy (26, 27) and PARP inhibitors (PARPi) (28, 29), and while PARPi have demonstrated their efficacy in advanced BRCA-deficient breast cancers (30), these”
BackgroundClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065 · cited 1×
“However, a simple correlation between DNA repair defects-induced genomic instability, TMB and response to ICI cannot be claimed (5), as tumor heterogeneity (13) and other determinants of response also play a role that, importantly, seems to be independent from TMB in response to ICI (14, 15).”
BackgroundNivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · cited 2×
“Very recent impressive results of large phase III trials in NSCLC have reported unprecedented improvements in overall survival and progression free survival when using anti-programmed death receptor 1 or -ligand 1 (anti-PD-(L)1) in first-line therapy (1, 2).”
Background
Research works printed but not linked: 1
- Robillard L. Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 PD-L1 inhibition in a syngenic BRCA2 mutant ovarian cancer model. Proceedings of the AACR. 2017;58(pt A):3650. Accessed January 7, 2019.
Cited by
Items 201–300 of 338
Han, L., Chen, Y., Huang, N. J., Zhou, X., Lv, Y.-F., Li, H., Chai, D., Zheng, J., & Wang, G. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0248 · Cited by 23
“PARP-1 inhibition enhances anti-tumor immunity in mouse models and lung cancer patients 23 .”
BackgroundCDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer
Liu, S., Deng, P., Yu, Z., Hong, J. H., Gao, J., Huang, Y., Xiao, R., Yin, J., Zeng, X., Sun, Y.-C., et al. (2024) · Advanced Science · doi:10.1002/advs.202403782 · Cited by 16
Therapeutic targeting of cGAS–STING pathway in lung cancer
Wang, J., & Xing, L. (2024) · Cell Biology International · doi:10.1002/cbin.12263 · Cited by 14
“…the cancer ‐ immunity cycle (CIC) in different ways, including antigen release and presentation besides priming, activation (Sivick et al., 2018), movement and infiltration of T cells into tumor tissues, supplemented by recognition and destruction of tumor cells by T cell (Chabanon et al., 2019).”
InfluentialTargeting DNA repair pathways: mechanisms and potential applications in cancer therapy
Bai, Y., Wang, W., & Wang, J. (2020) · Genome Instability & Disease · doi:10.1007/s42764-020-00026-7 · Cited by 16
Role of Base Excision Repair in Innate Immune Cells and Its Relevance for Cancer Therapy
Zhao, S., Habib, S. L., Senejani, A. G., Sebastian, M. M., & Kidane, D. (2022) · Biomedicines · doi:10.3390/biomedicines10030557 · Cited by 17
Juncheng, P., Joseph, A., Lafarge, A., Martins, I., Obrist, F., Pol, J. G., Saavedra, E., Li, S., Sauvat, A., Cerrato, G., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004280 · Cited by 16
Khaddour, K., Ansstas, M., & Ansstas, G. (2021) · Molecular Case Studies · doi:10.1101/mcs.a006129 · Cited by 15
“PARP inhibitors can enhance sensitivity in the tumor microenvironment to ICB through a variety of mechanisms including increased chromosomal aberrations due to deficiency in DNA repair pathways, and modulation of immune response in the tumor microenvironment (Teo et al. 2018; Chabanon et al. 2019).”
BackgroundSmith, D. E., Raíces, M., Cayol, F., Corvatta, F. A., Caram, L. J., & Dietrich, A. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.01.006 · Cited by 14
Gay, C. M., & Byers, L. A. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.004 · Cited by 14
Tumor microenvironment regulation - enhanced radio - immunotherapy
Yu, X., Wang, X., Sun, L., Yamazaki, A., & Li, X. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.212867 · Cited by 14
PARP in colorectal cancer: Molecular mechanisms, immunity, clinical trials, and drug combinations
Wu, F., Wei, H., Deng, H.-Y., Xiao, G.-H., & Zhang, Y. (2022) · Neoplasma · doi:10.4149/neo_2022_220724n745 · Cited by 16
DNA damage repair and cancer immunotherapy
Xiang, Z., Liu, H., & Hu, Y. (2023) · Genome Instability & Disease · doi:10.1007/s42764-023-00098-1 · Cited by 13
“The following end-bridging and alignment step is mediated by the coordinated action of PARP1, MRN and POLQ, another protein recruited to the DSB by PARP1, leading to the creation of non-homologous 3' tails 1 3 (Yousefzadeh et al., 2014).”
InfluentialPrognostic significance of STING expression in solid tumor: a systematic review and meta-analysis
Kim, Y.-H., Cho, N.-Y., Jin, L., Jin, H. Y., & Kang, G. H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1244962 · Cited by 13
Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
Kawachi, A., Lenormand, M. M., Astier, C., Herbel, N., Cutrona, M. B., Duong-Ngo, C., Garrido, M., Eychenne, T., Dorvault, N., Bordelet, L., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3603 · Cited by 12
“…reports, including ours, describing that PARPi and ATRi can trigger a cell-autonomous type I IFN response through the activation of the cGAS–STING pathway subsequent to micronuclei formation (41, 45–50), we decided to explore the ability of PARPi and ATRi to elicit such a response in DSRCT cells.”
Self-citationLi, Y., Wang, C., Zhou, S., Shi, Y., Zhu, D., & Zheng, X. (2026) · Cell Reports · doi:10.1016/j.celrep.2025.116854 · Cited by 15
Sicard, G., Fina, F., Fanciullino, R., Barlési, F., & Ciccolini, J. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080758 · Cited by 13
“However, the clinical results in terms of survival have failed to meet the initial expectations because only a minority of patients show long term survival, in a minority of cancer disease such as melanoma, NSCLC, head, neck, and kidney cancers.”
BackgroundInfluentialTayoun, T., Oulhen, M., Aberlenc, A., Farace, F., & Pawlikowska, P. (2021) · Cells · doi:10.3390/cells10020337 · Cited by 12
“Identification of cGAS/STING activators is an area of active research, with several ongoing clinical trials evaluating such molecules [28,29].”
BackgroundOncogenic RAS in Cancers from the DNA Replication Stress and Senescence Perspective
Técher, H., Kemiha, S., Xieraili, A., & Kolinjivadi, A. M. (2024) · Cancers · doi:10.3390/cancers16233993 · Cited by 11
“It has been further observed that PARP inhibition generates cytosolic DNA (in this case cytosolic chromatin fragments, CCFs, were observed) in an ERCC1-dependent manner in NSCLC cells [90,91].”
Tumor immunology and immunotherapy for endometrial cancer
Murakami, K., Takamura, S., Kakimi, K., & Matsumura, N. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2463091 · Cited by 10
“PARP inhibition by olaparib, rucaparib, and niraparib induced an antitumor immune response dependent on activation of the cGAS-STING pathway (Figure 2) in BRCA1/2-deficient tumors as well as BRCA wild-type tumors and enhanced the combined effect of anti-PD-1/PD-L1 antibody [38,48–52].”
PARylation-mediated post-transcriptional modifications in cancer immunity and immunotherapy
Matsumoto, K., Matsumoto, Y., & Wada, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1537615 · Cited by 13
Two decades of PARP inhibitor synthetic lethality in cancer
Lord, C. J., Tutt, A. N. J., & Ashworth, A. (2026) · Nature · doi:10.1038/s41586-026-10404-y · Cited by 19
Self-citationPostel-Vinay, S. C., Coves, J., Texier, M., Aldea, M. D., Gazzah, A., Dómine, M., Planchard, D., Peñas, R. D. L., González, M. A. S., Viteri, S., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02514-5 · Cited by 11
“Further translational studies are warranted to identify which molecular subset of NSCLC patients might truly bene fi t from PARPi.”
Self-citationKim, C., Wang, X., Liu, Z., Hao, J., Wang, S., Li, P., Zi, Z., Ding, Q., Jang, S., Kim, J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adh2579 · Cited by 11
Burazer, M. P., Mladinov, S., Matana, A., Kuret, S., Bežić, J., & Durdov, M. G. (2019) · Diagnostic Pathology · doi:10.1186/s13000-019-0885-2 · Cited by 11
Associating Immunotherapy and Targeted Therapies: Facts and Hopes
Ladoire, S., Rébé, C., & Ghiringhelli, F. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1184 · Cited by 11
Rosado, M. M., & Pioli, C. (2023) · Cancers · doi:10.3390/cancers15041093 · Cited by 11
“Clinically approved PARPis have been shown to induce IFN-I and CCL5 expression in tumor cells trough cGAS-STING [101].”
Hochmair, M. J., Schenker, M., Cobo, M., Kim, T. M., Özyılkan, Ö., Smagina, M. V., Viktoriya, L., Kato, T., Феденко, А. А., Angelis, F. D., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.10.012 · Cited by 10
Elucidating DNA Damage-Dependent Immune System Activation
Deligianni, E., Papanikolaou, C., Terpos, E., & Souliotis, V. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125849 · Cited by 12
Ozawa, Y., Koh, Y., Shibaki, R., Harutani, Y., Akamatsu, H., Hayata, A., Sugimoto, T., Kitamura, Y., Fukuoka, J., Nakanishi, M., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03861-9 · Cited by 10
“Activation of the cGAS/STING pathway in macrophages is capable of reprograming M2 macrophages into the M1 type [13, 29, 30].”
Background[Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer].
Guo, H., Bai, R., & Cui, J. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.02.05 · Cited by 12
PARP inhibition in prostate cancer
Nientiedt, C., Duensing, A. U., Zschäbitz, S., Jäger, D., Hohenfellner, M., Stenzinger, A., & Duensing, S. M. (2020) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22903 · Cited by 10
From targeted therapy to a novel way: Immunogenic cell death in lung cancer
Xu, J., Xiong, Y., Xu, Z., Xing, H., Zhou, L., & Zhang, X. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1102550 · Cited by 11
“Also, numerous studies have shown platinumbased combination chemotherapy and combination ICIs, like PD-1 or for its ligand PD-L1, can markedly prolong survival in patients with stage III unresectable NSCLC (204–207).”
BackgroundInfluentialZhao, N., Zhang, Z., Wang, Q., Li, L., Wei, Z., Chen, H., Zhou, M., Liu, Z., & Su, J. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104801 · Cited by 10
Yang, T., Wang, J., Huo, F., & Yin, C. (2025) · Chemical Communications · doi:10.1039/d5cc05711f · Cited by 9
The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer
Gillessen, S., & Bristow, R. G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30780-6 · Cited by 9
Pham, M. M., Hinchcliff, E., Avila, M., & Westin, S. N. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000562 · Cited by 9
Poly(ADP-ribose) polymerase-1 and its ambiguous role in cellular life and death
Castedo, M., Lafarge, A., & Kroemer, G. (2023) · Cell Stress · doi:10.15698/cst2023.01.275 · Cited by 9
“However, the cytotoxic effect of PARP1 inhibitors against cancer cells is mostly mediated by the trapping of PARP1 at sites of DNA damage that generates stalled replication forks during the S phase of the cell cycle [11-13].”
Fang, T., Xia, Y., Li, Y., Xu, S., Li, H., Wang, S., Huang, P., Qian, Y., Jin, P., Jin, N. Y., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2516294 · Cited by 8
“8,9 These observations provide a strong rationale for combination therapy with PARPi and immune checkpoint inhibitors.”
Chabanon, R. M., Shcherbakova, L., Lacroix‐Triki, M., Aglave, M., Zeghondy, J., Kriaa, V., Gougé, A., Garrido, M., Edmond, E., Bigot, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62309-5 · Cited by 9
Self-citationYadav, K., Das, T., & Lynn, A. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-99965-y · Cited by 9
Impact of DNA Damage Response—Targeted Therapies on the Immune Response to Tumours
Lutfi, N., Galindo-Campos, M. A., & Yélamos, J. (2021) · Cancers · doi:10.3390/cancers13236008 · Cited by 8
“Different mechanisms have been proposed to explain the upregulation of PD-L1 by PARPi, such as: inhibition of glycogen synthase kinase 3β (GSK3β) [74], resulting in PD-L1 stabilization [76]; IFN-γ-induced PD-L1 expression [44]; and suppression of nucleophosmin (NPM1) interactions with PARP1, thereby enhancing the asso…”
BackgroundInfluentialZhang, T., Zhang, C., Fu, Z., & Gao, Q. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091768 · Cited by 9
“PARP inhibitors, Olaparib and Rucaparib, have been proven to upregulate PD-L1 expression in small and non-small cell lung cancer [91,92].”
BackgroundPARP Inhibitors and Proteins Interacting with SLX4
Jordheim, L. P. (2023) · Cancers · doi:10.3390/cancers15030997 · Cited by 7
Bailey, M. M., Morand, S. M., Royfman, R., Lin, L., Singh, A. P., Stanbery, L., Walter, A., Hamouda, D., & Nemunaitis, J. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063173 · Cited by 7
“In patients with defective Excision Repair Cross-Complementation Group 1 (ERCC1), a particular homologous repair deficiency, with non-small cell lung cancer (NSCLC), PARPi therapy created cytoplasmic chromatin fragments that triggered cGAS/STING to produce type I IFNs and CCL5 [58].”
BackgroundStefens, S. J. M., van der Linden, J., Heredia‐Genestar, J. M., Brandt, R. M. C., Barnhoorn, S., Nieuwenhuizen‐Bakker, I., van Vliet, N., Odijk, J. H. M., Ridwan, Y. R., Stuijts, D., et al. (2025) · Aging Cell · doi:10.1111/acel.70062 · Cited by 6
The cGAS–STING pathway in cancer immunotherapy: prognostic value and therapeutic potential
Alabi, F. A., Imodoye, S. O., Adedokun, K. A., Eltokhy, M. A., Curcic, M., Okoyeocha, E., Thapa, I., Tiwari, S., Ogundele, A. V., Ayo, T. E., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1760947 · Cited by 7
Microglial inflammation in genome instability: A neurodegenerative perspective
Maliar, N. L., Talbot, E., Edwards, A. R., & Khoronenkova, S. V. (2024) · DNA repair · doi:10.1016/j.dnarep.2024.103634 · Cited by 7
PARP Inhibition in Advanced Prostate Cancer
Fenton, S. E., Chalmers, Z. R., & Hussain, M. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000560 · Cited by 7
The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors
Gueble, S. E., Vasquez, J. C., & Bindra, R. S. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01024-5 · Cited by 6
Hiatt, J. B., & MacPherson, D. P. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0234 · Cited by 6
Wang, Z., Embaye, K. S., Yang, Q., Qin, L., Zhang, C., Liu, L., Zhan, X., Zhang, F., Wang, X., & Qin, S. (2021) · Aging · doi:10.18632/aging.203315 · Cited by 6
“Sophie Postel-Vinay reported that PARP inhibition enhanced the intrinsic immunity of tumor cells in NSCLC with deficiency in excision repair cross-complementing group 1, a gene which has crucial role in the nucleotide excision repair [34].”
BackgroundcGAS-STING pathway in lung cancer and emerging therapeutic approaches
Joshi, A., & Izgü, E. Ç. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104646 · Cited by 6
Immunogenic cell death as a cornerstone for combination therapies with immune checkpoint blockade
Niu, Y., Zhu, S., Fu, K., Lai, Y. Y., Pan, C., Yang, Y., Li, S., Wang, X., To, K. F., Wang, F., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02663-0 · Cited by 7
Tilianin enhances the antitumor effect of sufentanil on non‐small cell lung cancer
Chen, H., Wu, Y., Wang, J., Li, Y., Chen, Y., Wang, X., Lv, H., & Liu, X. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23761 · Cited by 5
Zhang, L., Wang, Y., Qiao, R., Zhang, Y., Qiang, H., Du, H., Wen, F., Liu, M., Zhou, Y., Nie, W., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00035 · Cited by 5
Abualsoud, B. M., Alhomrani, M., Alamri, A. S., Alsanie, W. F., Ballal, S., Sharma, G. C., Krithiga, T., Singh, A., Kumar, A., & Deepak, A. (2025) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2025.2534698 · Cited by 7
Liang, Z., Xu, Y., & Li, C. (2025) · DNA repair · doi:10.1016/j.dnarep.2025.103874 · Cited by 7
Wang, L., Zhu, X., Li, L., Li, L., Li, F., Li, Y., Fu, H., Chen, X., & Lou, L. (2021) · PubMed · Cited by 5
Brooks, T., Wayne, J., & Massey, A. J. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00044-1 · Cited by 6
Targeting mitotic regulators in cancer as a strategy to enhance immune recognition
Gregorczyk, M., & Parkes, E. E. (2023) · DNA repair · doi:10.1016/j.dnarep.2023.103583 · Cited by 4
Yang, Z., Wang, L., & Kang, F. (2025) · International Journal of Cancer · doi:10.1002/ijc.35496 · Cited by 4
“…(1) intracellular pathogens [24 – 26] and (2) chemotherapeutic drugs: (1) traditional chemotherapy drugs; [27 – 29] (2) targeted anticancer drugs, [30 – 32] such as cyclin-dependent kinase (CDK) inhibitors; (3) other drugs, such as traditional Chinese medicine ingredients; (4) oncolytic viruses…”
Targeting KMT5C Suppresses Lung Cancer Progression and Enhances the Efficacy of Immunotherapy
Yuan, Y., Li, Q., Yan, G., Qian, Y., Guo, W., Li, S., Wang, F., Shang, W., Zhu, Z., Ge, D., et al. (2025) · Advanced Science · doi:10.1002/advs.202407575 · Cited by 6
McFarland, T. R., Kessel, A. C., Swami, U., & Agarwal, N. (2021) · PubMed · Cited by 5
Wu, Y., Zhang, X., Li, L., Yang, W., Yan, Z., Gu, C., Zhang, Z., Zhou, J., Liu, L., Ye, M., et al. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s375643 · Cited by 4
“PARPi has been found to enhance PD-L1 expression through several cellular pathways (eg, IFNY, STNG pathway, GSK3B).(14,15) At the same time, PARPi mediated DNA damage may enhance the anti-tumor immune response.”
BackgroundUnifying targeted therapy for leukemia in the era of PARP inhibition
Boila, L. D., & Sengupta, A. (2023) · Experimental Hematology · doi:10.1016/j.exphem.2023.05.005 · Cited by 4
Tumor microenvironment phenotyping guides precision therapy in unresectable pancreatic cancer
Zhao, K., Xiao, M., Yang, Y., & Xiao, X. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i10.109830 · Cited by 3
“…Patients with activated nucleotide excision repair pathways ( e.g. , ERCC1 ) may benefit from PARP inhibitors plus gemcitabine/nab-paclitaxel (ORR 38% vs 15%)[88], and ABC transporter overexpression-mediated resistance can be reversed by coadministration of P-gp inhibitors ( e.g. , verapamil)[89].”
Kjølle, S., Presti, M., Roque, J. D. P., Bisgaard, L. H., Ramos, D. B., Zornhagen, K. W., Yde, C. W., Schmidt, A. Y., Verdys, P., Højgaard, M., et al. (2026) · Cells · doi:10.3390/cells15030259 · Cited by 3
“The lack of efficacy may indicate that ATM alterations alone are insufficient to confer PARP inhibitor sensitivity, or that compensatory repair mechanisms and bypass activation contribute to resistance, consistent with emerging evidence of PARP inhibitor resistance [12,13].”
Feng, Y., Han, Z., Liu, X., Yao, S., Li, Y., Han, Y., & Xia, S. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116325 · Cited by 5
Nelen, I. H., Leys, S., Bekaert, S.-L., Vloed, F. D., Martens, F., Sanders, E., Raj, A. P. E., Jeschke, A., Ohmura, S., Grünewald, T. G. P., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08514-6 · Cited by 3
“5E).”
The DNA damage response and cancer immunotherapy
Sheng, H., & Li, G. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00958-4 · Cited by 6
“Both inherent deficiencies (for example, BRCA mutations) and therapeutically induced deficiencies (for example, with a PARPi) can create a unique vulnerability; they elevate TMB, activate the cGAS–STING pathway, and reshape the TME to favour immune recognition 25,80,244 .”
Characterization of the function and clinical value of ERCC family genes in lung adenocarcinoma
Lu, Z., & Hou, G. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1476100 · Cited by 3
Stange, C., Dreyer, T. F., Riedel, M., Elsen, F. A. V., Seitz, S., Hamann, D., Kiechle, M. B., & Bronger, H. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03076-4 · Cited by 4
“Activation of the cGAS/STING pathway by PARPi-induced accumulation of double-stranded DNA fragments in the cytosol of tumour cells initiates a type I interferon-like response with the release of the T cell-recruiting chemokines CCL5 and CXCL10, but also the upregulation of PD-L1 [10 – 12].”
Chabanon, R. M., & Postel-Vinay, S. C. (2019) · médecine/sciences · doi:10.1051/medsci/2019148 · Cited by 4
Self-citationComprehensive analysis of BRCA1/2 mutations, “BRCAness” and PARP inhibitors in melanoma
Stylianakis, D., Stylianakis, I., Benjamin, H. A., Martella, S., Tziotis, A., Pellegrino, B., Silva, P. D., Giannakis, M., Perrone, F., Lambertini, M., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104962 · Cited by 2
Liu, C., Xu, F., Wu, Y., Li, J., Mengdong, N., Xia, S., Chen, L., Haiyun, Z., Yu, M., Zhou, Y., et al. (2025) · Protein & Cell · doi:10.1093/procel/pwaf091 · Cited by 2
The molecular intersections of pulmonary fibrosis and lung cancer
Luo, B., Liu, X., Wang, S., Tong, Z., Han, Y., Tan, K., & Cao, P. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105042 · Cited by 2
PARP7 inhibition and a STING agonist potentiate radiation-induced immunogenicity in glioblastoma
Lippert, L., Kleinwächter, A., Ohradanova‐Repic, A., Horvat, F., Appel, L.-M., Walch, L., Bragato, N., Wimmer, J., Wopfner, H., Rohrer, A. M., et al. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2656053 · Cited by 2
The cGAS/STING pathway in cancer: translating innate DNA sensing into therapeutic potential
Wang, Y., Angulo-Lozano, J. C., Wang, Y., & Deng, L. (2026) · Journal of Clinical Investigation · doi:10.1172/jci204552 · Cited by 3
Single-cell morphological profiling reveals insights into programmed cell death
Frey, B. E., Holmberg, D., Bystrom, P., Bergman, E., Georgiev, P., Johansson, M. M., Hennig, P., Rietdijk, J., Rosén, D., Puigvert, J. C., et al. (2026) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2026.100181 · Cited by 2
Ma, J., Song, J., Yi, X., Zhang, S., Huang, L., Sun, L., Gao, R.-L., & Han, C. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112006 · Cited by 3
Xia, J., Shen, Y., Jiang, Q., Li, X., Yan, Y., Zhi, X., & Zhou, L. (2024) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000543 · Cited by 2
“20 The multifaced role of PARP-1 in both DNA impairment and immune levels in tumors underscores the necessity of further study on the relevance and potential regulatory relationship between PARP-1 and tumor immunotherapy.”
An Industry Update in Therapeutics: What is the Latest news?
Reis, C. P. (2019) · Therapeutic Delivery · doi:10.4155/tde-2019-0026 · Cited by 2
Recondo, G., & Mezquita, L. (2020) · Future Oncology · doi:10.2217/fon-2020-0707 · Cited by 2
Research progress on the treatment of advanced prostate cancer with Olaparib
Su, Y., Yu, C.-F., Xue, P., Li, L., Xiao, K., Chu, X.-L., & Zhu, S. (2021) · Neoplasma · doi:10.4149/neo_2021_210627n856 · Cited by 2
Macrophage barrier responses to oncogenic transformation
Blander, J. M. (2024) · Current Opinion in Immunology · doi:10.1016/j.coi.2024.102524 · Cited by 1
Li, L., Xiao, M., Zhang, L., Zhao, S., Zhang, G., Wu, S., Jin, C., Yang, J., & Lu, X. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.04.027 · Cited by 1
Azhar, M. S. M., Loh, Z., Mutamba, F. T., Algahiny, A., Yunusa, N. M., Paramasevon, S., & Almusarhed, M. (2025) · Cureus · doi:10.7759/cureus.99275 · Cited by 3
“PARP inhibition induces DNA damage and increases cytosolic DNA fragments, which activate the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway, driving type I interferon production and recruitment of dendritic cells and CD8+ T cells [21,25-28,30].”
Huang, Y., Yang, Y., Zhang, Q., & Wang, S. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105278 · Cited by 1
Chen, K., Gui, L., Chen, P., Wang, Z., Zheng, Z., Luo, W., Gao, W., & Ma, B. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158350 · Cited by 1
Ramalingam, S. S., Velcheti, V., Altan, M., de Castro, G., Thomas, M., Sanborn, R. E., Mazières, J., Schuler, M., Isaksson, J., Schenker, M., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.104087 · Cited by 1
PI3K/AKT signaling pathway: molecular crossroads in tumorigenesis and therapeutic innovation
Shi, Q., Liu, J., Chu, Q., Zeng, Y., Zhang, Y., Jiang, S., Yuan, X., Zhu, D., & Li, L. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02770-w · Cited by 1
“404,405 Genetic mutations associated with tumorigenesis frequently alter signaling pathways within tumor cells, such as the PI3K/AKT cascade, consequently affecting both the biological characteristics of the tumor and its immunogenic pro fi le (Fig.”
Stukan, А. I., Goryainova, А. Y., Викторович, Ш. С., Алексеевна, Г. О., Khachmamuk, Z. K., & Durov, V. V. (2022) · Tumors of female reproductive system · doi:10.17650/1994-4098-2022-18-1-54-65 · Cited by 1
Tan, Y., & Song, Q. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24452 · Cited by 1
“For instance, the DNA damage mediated by PARPi can regulate the immune microenvironment of tumor cells through a series of cellular mechanisms that further support the susceptibility of tumor cells to ICIs [2,39].”
BackgroundWu, D., Xu, Y., Wang, C., Xu, T., Gu, Y., Zhang, X., Wang, A., & Cui, H. (2025) · Oncology Letters · doi:10.3892/ol.2025.15113 · Cited by 1
“A retrospective study found that combining TMZ with programmed cell death protein‑1 (PD‑1)/programmed cell death‑ligand 1 (PD‑L1) inhibitors resulted in an ORR of 26.19% and a DCR of 64.29% in patients with NSCLC brain metastasis (15).”
InfluentialZhou, J., He, J., Lu, Y., Yi, C., Chang, X., Tao, L., Zhong, K., Zhang, H., Niu, H., Wang, X., et al. (2026) · Research · doi:10.34133/research.1265 · Cited by 2
“Recent studies have shown that PARP inhibitors can induce micronuclei formation in cancer cell lines and trigger the expression of ISGs in a cGAS-and STING-dependent manner [ 42 , 43 ].”
4-1BB is a target for immunotherapy in patients with undifferentiated pleomorphic sarcomaPreprint
Melake, M., Smith, H., Mansfield, D., Davies, E., Dillon, M. T., Wilkins, A., Patin, E. C., Pedersen, M., Buus, R., Miah, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.10.197293 · Cited by 1
Morel, D. (2020) · theses.fr (ABES) · doi:10.70675/d71744c6zd65ez4432z9296za7b978fd0dd6 · Cited by 1
Self-citationImmunotherapy as maintenance treatment in metastatic triple negative breast cancer
Tan, T. J., Chan, J. J., & Dent, R. A. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.20
Development of Immunotherapeutic Strategies for Early Phase Clinical Trials
Martín-Romano, P., Chabanon, R. M., Procureur, A., Aspeslagh, S., & Postel-Vinay, S. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-47682-3_15
Self-citationWu, X., He, J., Li, P., Wang, Y., Yan, L., & Ma, J. (2022) · PubMed · doi:10.12122/j.issn.1673-4254.2022.02.05
Metadata
- Authors
- Chabanon, R. M., Muirhead, G., Krastev, D. B., Adam, J., Morel, D., Garrido, M., Lamb, A., Hénon, C., Dorvault, N., Rouanne, M., Marlow, R., Bajrami, I., Cardeñosa, M. L., Konde, A., Besse, B., Ashworth, A., Pettitt, S. J., Haider, S., Marabelle, A., Tutt, A. N. J., Soria, J.-C., Lord, C. J., & Postel-Vinay, S.
- Affiliations
- Université Paris-Sud (FR)
- Breast Cancer Now (GB)
- Institute of Cancer Research (GB)
- Inserm (FR)
- Sage Bionetworks (US)
- King's College London (GB)
- University of California, San Francisco (US)
- ORCID
- Chabanon, Roman M.
- Krastev, Dragomir B.
- Adam, Julien
- Morel, Daphné
- Garrido, Marlène
- Lamb, Andrew
- Dorvault, Nicolas
- Rouanne, Mathieu
- Marlow, Rebecca
- Bajrami, Ilirjana
- Besse, Benjamin
- Ashworth, Alan
- Pettitt, Stephen J.
- Haider, Syed
- Marabelle, Aurélien
- Tutt, Andrew N.J.
- Soria, Jean-Charles
- Lord, Christopher J.
- Postel-Vinay, Sophie
- Venue
- Journal of Clinical Investigation
- Published
- 2019-02-11
- Volume
- 129
- Issue
- 3
- Pages
- 1211-1228
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6391116
- OpenAlex
- W2908418801
- Cited by
- 332
- References
- 62
- Citations by year
- 2026: 31 · 2025: 36 · 2024: 39 · 2023: 45 · 2022: 43 · 2021: 61 · 2020: 54 · 2019: 22
- FWCI
- 12.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- AstraZeneca
- Sanofi
- Merck KGaA
- Les Laboratories Pierre Fabre
- Fondation Philanthropia
- Cancer Research UK (14276, 25237, 24439)
- Institut National de la Santé et de la Recherche Médicale (INCa-DGOS-INSERM_12551)
- Institut National Du Cancer (INCa-DGOS-INSERM-12551)
- Institut Gustave-Roussy
- Direction Générale de l’offre de Soins
- Servier
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- PARP inhibitors, non-small cell lung cancer, triple-negative breast cancer, cGAS-STING pathway, cytosolic DNA sensing, type I interferon, PARP1, micronuclei, RANTES, PD-L1 expression, lymphocyte infiltration, olaparib, rucaparib, DNA repair deficiency
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, A549 Cells, STING Protein, Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase, Carcinoma, Non-Small-Cell Lung, DNA-Binding Proteins, Endonucleases, Female, Humans, Interferon-gamma, Lung Neoplasms, Membrane Proteins, Nucleotidyltransferases, BRCA1 Protein, B7-H1 Antigen, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.